GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer

ConclusionTaken together, GC1118 alone or in combination with cytotoxic chemotherapeutic agents exerted more potent anti-tumor effects than cetuximab in GC cells, regardless ofKRAS status. These findings support the further clinical development of GC1118 for the treatment of GC.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research